Founded July 2019
Stage Technology development
Investors Trendlines Incubators Israel, Bayer Trendlines Ag Innovation Fund
CEO Rudy Maor, PhD
The Company will leverage a disruptive technology for using bacteriophages, viruses that attack bacteria, for crop protection. The technology was developed by Professor Rotem Sorek of Israel’s Weizmann Institute of Science. Professor Sorek is a recognized world leader known for his groundbreaking research on the interactions between bacteria and bacteriophages.
Farmers’ need for effective, environmentally friendly solutions to combat bacterial diseases in crops prompted the effort to seek additional approaches. Bacteriophages have been recognized as natural enemies of bacteria for decades; yet, there has been a lack of technology for pinpointing the “right” phage combination to effectively fight disease, which inhibited acceptance for applications in agriculture.
In the Media
January 2020: Farmers and Bacteriophages Against Bacteria (Hebrew)
Orly has accumulated wide scientific-technological experience in diverse disciplines and holds strong business development capabilities. Prior to joining EcoPhage, Orly led the formation of a broad portfolio of technological licensing deals at Yeda R&D, the technology transfer arm of the Weizmann Institute of Science (WIS), where she served as a senior director of business development. As part of her role at Yeda, Orly initiated substantial multi-million commercialization achievements including startup spinouts, licensing deals and strategic collaborations, and business activities with MNCs, SMEs, VCs and accelerators, combining relations with the IIA and the academic staff.
Orly completed her PhD at the WIS biology & chemistry departments, and holds a MSc and BSc in engineering of biotechnology and food from the Technion, Israel Institute of Technology
Experienced biotechnology entrepreneur with a strong academic background; played a key role in the commercialization of technologies from academia through licensing and founding a start-up.
Led R&D teams that successfully generated significant results for the respective companies: generating value, raising funds, and forming strategic international collaborations; actively participated in the presentations and discussions that led to collaborations, joint ventures and licensing agreements, including the acquisition of Rosetta Green by Monsanto; PhD, molecular biology, Tel Aviv University